Please login to the form below
Orilissa
This page shows the latest Orilissa news and features for those working in and with pharma, biotech and healthcare.
Myovant preps US filing for relugolix in prostate cancer
Myovant is in a head-to-head battle with AbbVie and its rival GnRH inhibitor Orilissa (elagolix) in endometriosis-related pain and uterine fibroids, but has a clear run at the ... Orilissa has been approved in endometriosis and filed for uterine
Latest news
-
AbbVie files blockbuster hopeful elagolix for uterine fibroids
Will face competition from Myovant rival. AbbVie is gunning for the second indication for its new women’s health product Orilissa, hoping to add uterine fibroids to its FDA approval last ... The active ingredient in Orilissa – oral
-
Myovant has second phase 3 trial to back its uterine fibroids drug
Why? Because the jury is still out on whether Myovant can compete in the marketplace with AbbVie and its rival drug elagolix, which has already been approved as Orilissa for endometriosis
-
Myovant’s fibroids drug clears phase 3 trial, but shares sink
Their drug is already approved as Orilissa to treat endometriosis and has two positive phase 3 readouts in uterine fibroids in hand.
-
AbbVie preps uterine fibroid filing after phase 3 win
Second approval for Orilissa would boost blockbuster prospects. Armed with new phase 3 data, AbbVie is planning to file Orilissa for uterine fibroids, just a few weeks after getting approval for ... The results of two phase 3 trials showed that a six
-
AbbVie’s blockbuster-in-waiting for endometriosis gets FDA nod
The approval of elagolix – which will be sold as Orilissa and carry a list price of $845 per month – is a major step forward for AbbVie as it builds a portfolio ... Orilissa is billed as the first oral gonadotropin-releasing hormone (GnRH) antagonist
More from news
Approximately 2 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
Their performance in 2020, along with other new launches like Orilissa (elagolix) for endometriosis pain will be a signpost as to whether they can fulfil that potential.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- PMGroup announces launch of new recruitment platform PharmaRole
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- The state of pharma customer experience
- GSK and CureVac to advance mRNA COVID-19 and flu vaccine candidates
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
PMHub
Kardex
Kardex is a global industry partner for intralogistics solutions and a leading supplier of automated storage solutions and material handling...
Latest intelligence
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
